Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.
decitabine / cedazuridine
Decitabine / cedazuridine is a combination of a nucleoside metabolic inhibitor and a cytidine deaminase inhibitor. Decitabine exerts its effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation and/or apoptosis. Hypomethylation in cancer cells may restore normal function to genes that are necessary for control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA.
Cytidine deaminase (CDA) is an enzyme that catalyzes the degradation of cytidine, including the cytidine analog decitabine. Cedazuridine increases the systemic exposure of decitabine by inhibiting CDA in the gastrointestinal tract and liver that degrade decitabine and limit its oral bioavailability.
| Bioavailability |
Decitabine: Increased with cedazuridine Cedazuridine: 21% (range: 13% - 26%)
|
| Effects with food |
Decitabine: Administration with a high-fat, high calorie meal reduced the overall decitabine exposure (AUC0-8hr) and Cmax significantly. Cedazuridine: Administration with a high-fat, high calorie meal slightly delayed Tmax but systemic exposure was not affected.
|
| Peak plasma levels |
Decitabine: 1 hour (range: 0.3 to 3 hours) Cedazuridine: 3 hours (range: 1 to 8 hours)
|
| Time to reach steady state |
Steady state is achieved in 2 days. Decitabine AUC (from decitabine-cedazuridine) at steady state is equivalent to levels achieved with decitabine 20 mg/m2 IV infusion.
|
| PPB |
Decitabine: 5% Cedazuridine: 35%
|
| Main enzymes involved |
Decitabine: Primarily via cytidine deaminase (CDA) and by physiochemical degradation Cedazuridine: Conversion to epimer by physiochemical degradation
|
| Feces |
Cedazuridine: 51% (27% unchanged) |
| Urine |
Cedazuridine: 46% (17% unchanged) |
| Half-life |
Decitabine: 1.2 hours Cedazuridine: 6.3 hours
|
- Myelodysplastic syndromes (MDS)
- Chronic myelomonocytic leukemia (CMML)
Refer to the product monograph for a full list and details of approved indications.
Emetogenic Potential:
The following table lists adverse effects that occurred in > 10% of patients in all cycles in the pooled safety population. It also includes severe, life-threatening and post-marketing adverse effects from other sources.
| ORGAN SITE | SIDE EFFECT* (%) | ONSET** | |||
|---|---|---|---|---|---|
| Cardiovascular | Arrhythmia (11%) | E | |||
| Hypotension (11%) | E | ||||
| Dermatological | Other - acute febrile neutrophilic dermatosis (1%) | E | |||
| Rash (33%) | E | ||||
| Gastrointestinal | Abdominal pain (19%) | E | |||
| Anorexia, weight loss (24%) | E | ||||
| Constipation (44%) | E | ||||
| Diarrhea (37%) | E | ||||
| Enterocolitis (may be severe) | E | ||||
| Mucositis (41%) | E | ||||
| Nausea, vomiting (40%) | E | ||||
| General | Edema (30%) (<1% severe) | E | |||
| Fall (12%) | E | ||||
| Fatigue (55%) (5% severe) | E | ||||
| Hematological | Myelosuppression ± infection, bleeding (62%) (54% severe; including CNS, GI bleeding up to 7%) | E | |||
| Other - Differentiation syndrome (rare) | E | ||||
| Hepatobiliary | Other - ↑ serum transaminase (21%) | E | |||
| Hypersensitivity | Anaphylaxis (rare) | E | |||
| Metabolic / Endocrine | Tumour lysis syndrome (<1%) | E | |||
| Musculoskeletal | Musculoskeletal pain (42%) | E | |||
| Nervous System | Dizziness (33%) | E | |||
| Headache (30%) | E | ||||
| Insomnia (12%) | E | ||||
| Neuropathy (13%) | E | ||||
| Renal | Creatinine increased (18%) | E | |||
| Respiratory | Cough, dyspnea (38%) | E | |||
| Interstitial lung disease (rare) | E | ||||
* "Incidence" may refer to an absolute value or the higher value from a reported range.
"Rare"
may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies,
isolated data or anecdotal
reports.
** I = immediate (onset in hours to days)
E = early (days to weeks)
D = delayed (weeks to months)
L = late (months to years)
The most common side effects for decitabine / cedazuridine include myelosuppression ± infection, bleeding, fatigue, constipation, musculoskeletal pain, mucositis, nausea, vomiting, cough, dyspnea, diarrhea, dizziness and rash.
Fatal and serious myelosuppression can occur with decitabine / cedazuridine. Myelosuppression (thrombocytopenia, neutropenia, anemia, and febrile neutropenia) is the most frequent cause of dose reduction or interruption, occurring in 36% of patients. Permanent discontinuation due to myelosuppression (febrile neutropenia) occurred in 1% of patients.
Fatal and serious infectious complications can occur with decitabine / cedazuridine. Fungal infections, severe pneumonia and sepsis have been observed. Rare fatalities due to pneumonia, sepsis, and septic shock were also reported.
Serious anaphylactic reactions have been reported with decitabine. Hypersensitivity reactions have been reported with intravenous decitabine and decitabine / cedazuridine. Rash is reported in early cycles of decitabine / cedazuridine and diminishes with later cycles.
Refer to protocol by which patient is being treated.
Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the hepatitis B virus screening and management guideline.
Do not substitute decitabine / cedazuridine for an IV decitabine product within a cycle.
*1 tablet contains 35 mg of decitabine and 100 mg of cedazuridine
Do not modify the recommended dose for the first 2 cycles.
Hematologic Toxicity
Dosage Reduction for Myelosuppression:
| Dose Level | Decitabine / Cedazuridine Dose |
| 0 | 1 tablet once daily on days 1 through 5 |
| -1 | 1 tablet once daily on days 1 through 4 |
| -2 | 1 tablet once daily on days 1 through 3 |
| -3 | 1 tablet once daily on days 1, 3, and 5 |
Dose modifications in the absence of active disease:
| Toxicity | Decitabine / Cedazuridine Dose |
| ANC < 1 x 109/L and/or Platelets < 50 x 109/L |
Hold, and:
|
*ANC ≥ 1 x 109/L and Platelets ≥ 50 x 109/L
Non-hematologic Toxicity
| Toxicity | Decitabine / Cedazuridine Dose |
| Serum creatinine ≥ 176.8 µmol /L |
Delay treatment until resolved; manage patient appropriately. Resume at same dose level or at 1 dose level ↓ (e.g., administer fewer days per cycle). |
| Bilirubin ≥ 2 x ULN | |
| ALT or AST ≥ 2 x ULN | |
| Active or uncontrolled infection | |
| Severe hypersensitivity | Discontinue; manage patient appropriately. |
| Hepatic Impairment | Decitabine / Cedazuridine Starting Dose |
| Mild (bilirubin > 1 to ≤ 1.5 × ULN) | No dosage adjustment necessary. |
| Moderate (bilirubin > 1.5 to 3 x ULN) | No data available. |
| Severe (bilirubin > 3 × ULN) |
|
Creatinine Clearance (mL / min) |
Decitabine / Cedazuridine Starting Dose |
| ≥ 60 | No dosage adjustment necessary. |
| ≥ 30 to 59 | No dosage adjustment necessary; monitor for increased incidence of adverse reactions. |
| 15 to 29 | Use with caution; No data available. |
| < 15 (ESRD) |
No adjustment required. Overall, no differences in efficacy and safety were observed between patients ≥ 65 years and younger patients.
Safety and efficacy in children have not been established.
-
Administer at approximately the same time each day for 5 days in each cycle.
-
Tablets should be swallowed whole with water; do not cut, crush, or chew.
-
Decitabine / cedazuridine should be taken on an empty stomach; do not consume food 2 hours before and 2 hours after each dose.
-
Missed dose:
-
If the missed dose is within 12 hours of the time it is usually taken, administer the missed dose as soon as possible and then resume the normal daily dosing schedule.
-
If dose is missed by more than 12 hours of the time it is usually taken, the patient should wait and take the missed dose the following day at the usual time and extend the dosing period by 1 day for every missed dose to complete 5 daily doses for each cycle.
-
-
If a dose is vomited, do not administer an additional dose, continue with the next scheduled dose.
- Store tablets in original packaging at room temperature (15 to 30°C).
- Patients who have a hypersensitivity to this drug or any of its components
- Caution with driving or using machinery as fatigue or dizziness may occur with treatment due to anemia.
- Contains lactose; carefully consider use in patients with hereditary galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption.
Other Drug Properties:
-
Carcinogenicity:
No information available
-
Mutagenicity:
Yes
-
Genotoxicity:
Yes
-
Fetotoxicity:
Yes
-
Pregnancy:
Decitabine / cedazuridine is not recommended for use in pregnancy.
- Adequate contraception should be used by patients who can become pregnant and their partners during treatment, and for at least 6 months after the last dose
- Adequate contraception should be used by patients who produce sperm and their partners during treatment, and for at least 3 months following the last dose.
-
Excretion into breast milk:
Likely
Breastfeeding is not recommended during decitabine / cedazuridine treatment and for at least 2 weeks after the last dose.
-
Fertility effects:
Probable
Documented in animal studies. Discuss fertility preservation with patients prior to starting treatment.
Drug-drug interaction studies were not conducted with decitabine or cedazuridine.
Decitabine is not a substrate for P450 and did not inhibit or induce cytochrome P450 enzymes in vitro. Cedazuridine is not a substrate or modulators of CYP enzymes or major transporters, therefore, CYP450-mediated drug-drug interactions are unlikely.
Decitabine / cedazuridine is not expected to affect P-glycoprotein (P-gp) mediated transport of co-administered medicinal products as decitabine is a weak inhibitor of P-gp, and cedazuridine is neither a substrate nor an inhibitor of transporters including P-gp, MDR1, BCRP, MATE and OAT.
| AGENT | EFFECT | MECHANISM | MANAGEMENT |
|---|---|---|---|
| CDA substrates (i.e. cytarabine, gemcitabine, azacitadine, zidovudine, lamivudine, abacavir, emtricitabine, tenofovir, adefovir, entecavir, trifluridine) | ↑ substrates concentration and/or toxicity | Cedazuridine is an inhibitor of the CDA enzyme. | Avoid co-administration with drugs metabolized by CDA |
| Gastric pH Modifying Agents (i.e. proton pump inhibitors, H2 antagonists) | ↑ decitabine / cedazuridine concentration and/or toxicity | ↑ dissolution with increased pH | Avoid gastric acid reducing agents within 4 hours of decitabine / cedazuridine administration |
Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.
Refer to the hepatitis B virus screening and management guideline for monitoring during and after treatment.
| Monitor Type | Monitor Frequency |
|---|---|
CBC |
Baseline, prior to each cycle, and as clinically indicated |
Renal function tests |
Baseline and as clinically indicated |
Liver function tests |
Baseline and as clinically indicated |
Clinical toxicity assessment for infection, bleeding, fatigue, rash, hypersensitivity, tumour lysis syndrome, differentiation syndrome, GI and respiratory effects. |
At each visit |
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
Exceptional Access Program (EAP Website)
- decitabine / cedazuridine - For the treatment of adult patients with myelodysplastic syndromes (MDS), according to clinical criteria
Inqovi (decitabine/cedazuridine). Prescribing Information. Princeton, NJ: Taiho Oncology, Inc., July 2020.
Inqovi (decitabine/cedazuridine) Product Monograph. Oakville, Ontario: Taiho Pharma Canada Inc., July 2020.
February 2025 Updated Pregnancy and Lactation section
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.